STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCVX
  4. [Form 4] Vaxcyte, Inc. Insider Trading Activity

Vaxcyte (PCVX) director receives RSU and option grants with 2027 vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. director Halley E. Gilbert received new equity awards from the company. He was granted 2,265 restricted stock units, each representing one share of common stock, which will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to his continuous service.

He also received stock options for 11,389 shares of common stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These options vest monthly and will be fully vested on the same earlier-of-2027-or-next-meeting schedule. Following the RSU grant, he directly holds 12,481 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Gilbert Halley E
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 11,389 $0.00 --
Grant/Award Common Stock 2,265 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 11,389 shares (Direct, null); Common Stock — 12,481 shares (Direct, null)
Footnotes (1)
  1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
RSUs granted 2,265 units Restricted stock units granted to director on June 15, 2026
Stock options granted 11,389 options Option grant to buy common stock on June 15, 2026
Option exercise price $49.56 per share Exercise price for 11,389 stock options
Option expiration date June 15, 2036 Expiration of stock options granted to director
Shares held after grant 12,481 shares Director’s direct common stock holdings following RSU grant
restricted stock units financial
"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Option (right to buy) financial
"Stock Option (right to buy)"
exercise price financial
"The shares of Common Stock subject to the option will vest monthly"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
continuous service financial
"subject to the Reporting Person's continuous service through such date."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gilbert Halley E
(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
(Street)
SAN CARLOS CALIFORNIA 94070
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026A2,265(1)A$012,481D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$49.5606/15/2026A11,389 (2)06/15/2036Common Stock11,389$011,389D
Explanation of Responses:
1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Remarks:
Halley E. Gilbert, by /s/ Peter N. Efremenko, Attorney-In-Fact06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vaxcyte (PCVX) director Halley E. Gilbert report?

Halley E. Gilbert reported receiving equity awards from Vaxcyte, Inc., including restricted stock units and stock options. These awards are compensation grants, not open-market purchases or sales, and depend on his continued service with the company through the specified vesting dates.

How many Vaxcyte (PCVX) restricted stock units did the director receive?

He received 2,265 restricted stock units, each linked to one share of Vaxcyte common stock. These RSUs will fully vest on the earlier of June 15, 2027 or the day before the next annual stockholder meeting, assuming he continues serving the company until that date.

What stock options were granted to the Vaxcyte (PCVX) director and at what price?

He was granted options to purchase 11,389 shares of Vaxcyte common stock at an exercise price of $49.56 per share. These options vest monthly and will be fully vested by the earlier of June 15, 2027 or the day before the next annual stockholder meeting.

When do the new Vaxcyte (PCVX) RSUs and options vest for the director?

Both the 2,265 RSUs and the 11,389 stock options follow the same vesting framework. The RSUs fully vest and the options finish monthly vesting on the earlier of June 15, 2027 or the day prior to Vaxcyte’s next annual meeting, subject to continuous service.

What are the director’s Vaxcyte (PCVX) common stock holdings after this Form 4?

After the reported RSU grant, Halley E. Gilbert directly holds 12,481 shares of Vaxcyte common stock. This figure reflects his direct ownership position following the non-cash equity award recorded in the Form 4 insider transaction report.

When do the newly granted Vaxcyte (PCVX) stock options expire?

The stock options granted to Halley E. Gilbert expire on June 15, 2036. He can exercise them after vesting, at an exercise price of $49.56 per share, so long as he meets the service conditions and the options remain unexpired and outstanding.